A multi-arm, phase 2, open-label study to assess the efficacy of RXC004 as monotherapy and in combination with nivolumab in patients with ring finger protein 43 (RNF43) or R-spondin (RSPO) aberrated, metastatic, microsatellite stable colorectal cancer following standard treatments
Authors
Kopetz, S.Morris, V. K.
O'Neil, B.
Bridgewater, J. A.
Graham, J.
Parkes, E. E.
Saunders, Mark P
Asken, E.
Goodwin, L.
Phillips, C.
Robertson, J.
Tilston, C.
Woodcock, S.
Cook, Natalie
Affiliation
The University of Texas MD Anderson Cancer Center, Houston, TXIssue Date
2022
Metadata
Show full item recordCitation
Kopetz S, Morris VK, O'Neil B, Bridgewater JA, Graham J, Parkes EE, et al. A multi-arm, phase 2, open-label study to assess the efficacy of RXC004 as monotherapy and in combination with nivolumab in patients with ring finger protein 43 (RNF43) or R-spondin (RSPO) aberrated, metastatic, microsatellite stable colorectal cancer following standard treatments. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680304904.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2022.40.16_suppl.TPS3637Type
Meetings and Proceedingsae974a485f413a2113503eed53cd6c53
10.1200/JCO.2022.40.16_suppl.TPS3637